Results 181 to 190 of about 5,476,681 (324)

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky   +8 more
wiley   +1 more source

Hospitales reformando al mundo verde

open access: yesCiencia y Cuidado, 2016
Introducción: factores ambientales como el cambio climático, el calentamiento global, el mal uso del suelo y del agua, la mala administración de los recursos naturales, la contaminación del aire en espacios abiertos y cerrados, el crecimiento urbano y la
Sandra Milene Rojas-Criollo
doaj  

Predicting Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex Using a Fusion Model Integrating Lesion Network Mapping and Machine Learning

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Accurate localization of epileptogenic tubers (ETs) in patients with tuberous sclerosis complex (TSC) is essential but challenging, as these tubers lack distinct pathological or genetic markers to differentiate them from other cortical tubers.
Tinghong Liu   +11 more
wiley   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

[The silent impact of climate change on our mental health: Anxiety and stress in a changing world]. [PDF]

open access: yesAten Primaria
Torres Tejera ME   +3 more
europepmc   +1 more source

Whole‐Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To characterize whole‐body intramuscular fat distribution pattern in patients with sarcoglycanopathies and explore correlations with disease severity, duration and age at onset. Methods Retrospective, cross‐sectional, multicentric study enrolling patients with variants in one of the four sarcoglycan genes who underwent whole‐body ...
Laura Costa‐Comellas   +39 more
wiley   +1 more source

[Planetary Health from a prevention and health promotion perspective]. [PDF]

open access: yesAten Primaria
Del Campo Giménez M   +4 more
europepmc   +1 more source

La insolvencia: una salida de alivio financiero para personas naturales no comerciantes

open access: yes, 2021
Introducción 1. Estado del Arte. 2. Marco histórico de insolvencia 3. Conceptualización de la insolvencia en persona natural no comerciante 4. Decretos expedidos en ocasión al Covid-19 5. Análisis de los Proyectos de Ley radicados respecto a la insolvencia en persona natural no comerciante en tiempos de Covid-19 Conclusiones ...
openaire   +1 more source

Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy